AQS top value for 2019I'm amazed how little attention this company is still getting from investors. In my opinion this could be the ultimate rocket for 2019. One of the few Canadian biotech pennystocks that have a credible, sustainable business strategy with high potential for success. Their success does not rely on a single product or the "unicorn blockbuster", they have several low risk streams to generate revenue growth, to get to break even and then be able to fund themselves high revenue opportunities to further skyrocket their revenue and profit.
Note that AQS only requires around 5Mio CAD of revenue per year for break even (very low cash burn rate, very effective company).
I'd like to copy & paste a (not even complete) summary of AQS' potential from another user of another forum:
"Wow, just looking at how ZEPTO has been received in the market, apparently is makes average Surgeons into great Surgeons and even can extend their Careers. A well trained Surgeon usually performs a Cataract Surgery in 25-30 mins and the ZEPTO device can shorten that to 5 minutes. I hope all here understand the financial impact that can have on a practice as they bill the same amount regardless of duration. It can turn most Surgery Suites into an Assembly Line. As more and more Surgeons realize this they will be jumping on board. On top of al that the Capsulotomy as more cetration with more precise capsular walls that resist tears and an avoid fibrotic changes giving better vision and long term success for the Surgeon. Start up costs are nominal at retail $200 / Patient vs. about $300000 USD for a Femtolaser. With 300,000 Patients per year in Canada getting Cataract there is an endless supply if ZEPTO goes beyond the complex 30,000 cases to the more routine (which I believe it will). I think it also gives our Salespeople a whole new market and access for VISTITAN. I think the two products combined can easily do $7-$8 million / year in the next months ahead, maybe over $10 million as ZEPTO becomes more mainstream.
I can't even comprehend what the rumoured additional products we are supposed to be adding can add up to or the PRESERVATIVE FREE DROP that is coming in 2020? Now we learn that the company is on the cusp of starting a TROKENDI XR Trial that is just 60 Patients and this will add $20-$25 million to the top line in 2020. There has been no news from the Company but from others out there apparently we are looking at multiple updates coming VERY soon. This stock literally has the ability to jump to $.50-$1.00 / share overnight and depending on the news $1.50 is not outta the question. I'm guessing we start to see news hit this week or next and then a flurry of "developments" culminating in the "game changer" by end of March.... Good Luck Longs!!!"
Also note that the trials for Trokendi XR is a low-risk, low-cost bioequivalence study only, for a compound that already has market approval from the regulatory authorities.
AQS indicated that more product will be licensed for Canada soon and there are rumours about an interesting cannabis deal (probably a cannabis patch, for which they announced a partnership around one year ago). And much more is to come later on when they initiate the regulatory approval processes for their own products AQS-1301 and AQS-1303. Check their website for more info in case you are curious.
Needless to say that with a market cap of ~18Mio CAD at the moment this stock is highly undervalued.